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A B S T R A C T   
Background: Photodynamic therapy (PDT) is a promising treatment option for recurrent sinonasal malignancies. 
However, light administration in this area is challenging given the complex geometry, varying tissue optical 
properties and difficult accessibility. The goal of this study was to estimate the temporal and spatial variation in 
fluence and fluence rate during sinonasal mTHPC-mediated PDT. It was investigated whether the predetermined 
aim to illuminate with a fluence of 20 J⋅cm  2 and fluence rate of 100 mW⋅cm  2 was achieved. 
Methods: In eleven patients the fluence and fluence rates were measured using in vivo light dosimetry at the target 
location during real-time sinonasal PDT. There was a variance in sinonasal target location and type of light 
diffuser used. In four patients two isotropic detectors were used within the same cavity. 
Results: All measurements showed major fluence rate fluctuations within each single isotropic detector probe 
over time, as well as between probes within the same cavity. The largest fluence rate range measured was 328 
mW⋅cm  2. Only one probe showed a mean fluence rate of ~100 mW⋅cm  2. Taken all probes together, a fluence 
rate above 80 mW⋅cm  2 was measured in 31 % of the total light exposure; in 22 % it was less than 20 mW⋅cm  2. 
Thirty-three percent showed a fluence of at least 20 J⋅cm  2. 
Conclusions: The current dosimetry approach for sinonasal intra-cavity PDT shows major temporal and spatial 
variations in fluence rate and a large variance in light exposure time. The results emphasize the need for 
improvement of in vivo light dosimetry and dosimetry planning.   
1. Introduction 
In order to induce an optimal treatment effect of Photodynamic 
Therapy (PDT) it is essential that the three basic components of PDT (i.e. 
photosensitizer, light and oxygen) come together in the appropriate 
amount at the target location. Since the development of PDT, research 
has been implemented to further improve the treatment, for example by 
photosensitizer advancement or by refinement of the light application 
by using light dosimetry [1–6]. Among many treatment variables, a too 
low, or conversely too high light fluence rate is associated with a 
reduced cell response and depletion of the photosensitizer or oxygen 
within the cells, which finally result in a reduced PDT effect and an 
inadequate tumor response [1–5,7]. If using the photosensitizer 
meta-tetraHydroxyPhenylChlorin (mTHPC or Foscan®) in the treatment 
of head and neck tumors, a light dose of approximately 20 Joules⋅cm  2 
with a fluence rate of 100 mWatt⋅cm  2 has been clinically proven to 
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induce the desired clinical response [8–11]. 
For surface PDT the dosimetry (the delivered light dose (fluence) and 
fluence rate) is straightforward, based on the laser source output power 
(mW) and target surface area (cm2). The surrounding healthy tissue 
needs to be shielded by green cloth or black wax to prevent from un-
intended damage, because of back scattering of the light. Previously 
experiences with PDT in hollow organs such as the esophagus and 
bladder showed that the actual delivered fluence rate in a hollow cavity 
could be significantly higher than the primary fluence rate, due to re- 
emitting and reflection of photons by the (healthy) tissue within the 
cavity. This compared to the straightforward surface PDT where the 
target area is completely isolated [12–17]. In these target areas, it is 
challenging, otherwise non-feasible to cover the surrounding healthy 
tissue that influences this back-scattering component. Light delivery 
applicators in conjunction with in vivo dosimetry have been developed 
for this purpose, to be able to illuminate these complex target areas such 
as the nasopharynx or lung [18,19]. 
Several studies have investigated the use of PDT in the head and neck 
area over the past two decades, although, treatment of (recurrent) ma-
lignant tumors of the nasal cavity and paranasal sinuses (including the 
maxillary, ethmoid and sphenoid sinus and nasopharynx) is still fairly 
recent [8,9,20–22]. Malignant tumors of these cavities recur frequently 
after the ‘golden standard’ treatment, which is surgery and adjuvant 
(chemo)radiotherapy. The vicinity of essential structures (e.g. eyes, 
brain, cranial nerves etcetera) limits additional treatment options such 
as salvage surgery or re-radiation, where PDT is a potentially promising 
treatment option in case of recurrences [20,22]. The paranasal sinuses 
have a very complex geometry as for example compared to the oral 
cavity, trachea or bladder. In addition, endoscopic survey of these 
post-surgical cavities reveals a variety of tissue types at the cavity sur-
face (e.g.. mucosa, bone, fibrosis, mucus, crusts etcetera), which result in 
variable tissue optical properties. It is therefore to be expected that these 
geometries create regions with over and under illuminated areas. 
In this dosimetric pilot study, we aim to gain insight in the light 
delivery approach within the sinonasal cavity by measuring the fluence 
rate and fluence (i.e. light dose) in vivo at the target area within the nasal 
cavity, paranasal sinuses and nasopharynx during mTHPC-mediated 
PDT. The goal was to illuminate the target area with a fluence rate of 
100 mW⋅cm  2 and to deliver a fluence of 20 J⋅cm-2, based on source 
output power and tissue surface area without taking back scattering into 
account. 
2. Materials and methods 
2.1. Patients 
In situ dosimetry was performed in eleven patients (A-K) receiving 
mTHPC-mediated superficial PDT to treat (recurrent) sinonasal malig-
nancies (see Table 1). All patients were treated between January 2015 
and May 2017 in the Netherlands Cancer Institute/Antoni van Leeu-
wenhoek Hospital, Amsterdam, the Netherlands. The study was in 
accordance with the Helsinki declaration and approved by the medical 
ethics committee. Because of the 8  10 mm tissue penetration depth of 
the 652 nm light, the inclusion for PDT treatment was a tumor thickness 
of less than 5 mm. Tumors with more than 5 mm thickness were first 
(partially) surgically resected prior to the PDT treatment. The time in-
terval between the surgery and the PDT treatment was set to at least 6 
weeks to allow the tissue to recover and to minimize any negative 
impact from the wound surface during PDT such as blood loss or crusts 
[22]. Fig. 1 shows the CT imaging of patient C with a sphenoid sinus 
malignancy prior to (A) and after (B) the salvage surgery, previous to 
PDT. The photosensitizer mTHPC® (Biolitec Pharma, Bonn, Germany) 
was administered in a proximal arm vein with a dose of 0.15 mg/kg 
body weight according to the standard dose approved by the European 
Medicines Agency [23]. 
2.2. Pre-planning of the PDT illumination 
In all patients, the target area for the light exposure was determined 
prior to the PDT, based on the findings during clinical examination 
combined with Computed Tomography (CT) or Magnetic Resonance 
(MR) imaging. A basic illumination plan was made previous to the PDT, 
based on the light source output power (Pout in mW) together with the 
source location (source to target distance r) and size of the target surface 
area (A). An attempt was made to determine the optimum distance be-
tween the center of the light source and the target area (r in cm2) using 
the CT and MR data. This in order to define the most favorable or 
‘optimal’ light source position within the sinonasal cavity, to reach a 
fluence of 20 J⋅cm  2 and fluence rate of 100 mW⋅cm  2. In two patients it 
was decided before the PDT, to illuminate with a maximum fluence of 10 
J⋅cm  2 to limit damage to critical surrounding structures, adjacent to 
the target area. Depending on the location and shape of the target area, it 
was determined which type of light source diffuser was the most 
applicable to access the target area. A linear diffuser was chosen to 
illuminate a luminal shaped target area. During illumination of the 
nasopharynx, the linear diffuser was inserted in the nasopharynx 
applicator [19]. To calculate the surface area A in case of the linear 
diffuser, the equation A  2⋅π rL was used. Whereas L is the length of the 
target area. The output power of the linear diffuser was set at 100 
mW⋅cm-2. A micro-lens diffuser, providing a feasible perpendicular 
illumination, was employed in the case of an easily accessible target area 
within the sinonasal cavity. The surface area was estimated according to 
the equation Aπ⋅r2. If illumination with the micro-lens diffuser was not 
feasible, approximating a more concave shape and large target area, a 
spherical diffuser was used (all diffusers types; Medlight SA, Ecublens, 
Switzerland). To calculate the surface area for the spherical diffuser the 
equation A  4⋅π⋅r2 was used. 
2.3. PDT illumination and in situ dosimetry 
Four days after mTHPC administration, the PDT took place under 
general anesthesia at the operating theatre. A 2 W diode laser producing 
a continuous wave of light at 652 nm was used (Ceralas PDT, Biolitec, 
Bonn, Germany), which was calibrated in air in an incorporated inte-
grating sphere. The output of the diode laser was set, dependent on the 
predetermined light diffuser used, with a range of 0.1 to 0.9 W. The 
source was maneuvered manually under endoscopic surveillance by the 
surgeon to the preferable location as the prior estimated light source to 
target area surface distance r. Details on the target location and type of 
light diffuser used are given in Table 1. If feasible, the healthy tissue 
Table 1 
An overview of the patients in whom light dosimetry measurements were per-
formed in vivo during sinonasal PDT. The anatomical position of the target area, 
the number of isotropic detector probes used during the measurement within the 
target area and the type of light source diffuser (linear, spherical or microlens) 
are shown.  
Patient Target area (Tumor 
location) 
Number of isotropic 
detector probes 
Type of light 
diffuser 
A nasopharynx 2 linear 
B nasopharynx, sphenoid 
sinus 
1 linear 
C sphenoid sinus, anterior 
skull base 
2 spherical 
D maxillary sinus 1 microlens 
E maxillary sinus 1 spherical 
F maxillary sinus 1 spherical 
G sphenoid sinus, anterior 
skull base 
2 spherical 
H maxillary sinus 2 microlens 
I nasopharynx 1 linear 
J frontal sinus 1 microlens 
K nasopharynx 1 linear  
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surrounding the target area was covered with wet green drapes or black 
wax to prevent accidental light exposure, although in most locations 
covering was not possible, with the exception of the built-in covering of 
the nasopharynx applicator. 
Real-time, during PDT illumination, the fluence and fluence rate on 
the surface of the target area were determined in vivo by using a 
dosimetry device (NI PXI-1045 18-slot Chassis, National Instruments) 
[19]. Isotropic light detector probes with a 0.865 mm distal tip diameter 
and a 400 μm core diameter (model IP85, Medlight S.A., Ecublens, 
Switzerland) were connected to the device. To protect the fragile 
spherical tip, the isotropic probes were inserted into a proguide brachy 
catheter (Proguide Round Needle Set, 6 F, Elekta, Stockholm, Sweden) 
The isotropic detector probes measure the total fluence rate, i.e. the 
direct irradiance emitted by the light source together with the fluence 
rate caused by tissue back scattering within the cavity. Prior to the 
measurements the isotropic detector probes were calibrated in air, 
making use of an integrating sphere illuminated by baffle shielded light 
emitting diodes (LED’s), generating a homogeneous stable reference 
fluence rate field. The dosimetry device (LabVIEW™) gives an overview 
of the fluence rate and fluence plotted over light exposure time per 
single isotropic detector probe. Depending on the perioperative space, 
one or two isotropic detector probes were placed manually by the sur-
geon in the target area. The probes were hand-held by the surgeon at the 
same location during the illumination to yield a value for total fluence 
delivered at the spot investigated. In Fig. 1C a 3 dimensional render 
reconstruction of the dosimetry measurement with two isotropic de-
tector probes during PDT illumination is shown. This reconstruction is 
based on the CT imaging of patient C. An example of the PDT and 
dosimetry measurement set up in the operation room is shown in Fig. 2. 
As shown in Fig. 2A and B the sinonasal cavity has an irregular shape 
and can be small to work in with the surgical tools. 
2.4. Data analysis 
The dosimetry device measures and stores the fluence rate, fluence (i. 
e. light dose) and light exposure time per single isotropic detector probe 
Fig. 1. (A) CT-scan in the sagittal plane of patient C with a tumor located in the sphenoid sinus (asterisk *) prior to any treatment. (B) CT-scan of the same patient 
after salvage surgery of the tumor, prior to PDT. The asterisk (*) shows the sphenoid sinus and the target area of the PDT. (C) 3D render reconstruction from the CT 
imaging of patient C prior to the PDT treatment. The white tubes represent the two isotropic detector probes. The red bulb indicates the spherical light diffuser with 
the light reflection on the sphenoid sinus surface. 
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per second. The fluence rate and fluence measurements were analyzed 
for each single probe. If the illumination was interrupted (e.g. for re- 
positioning of the light source or in case of source or shielding shifts 
during the manually guided illumination; to secure the healthy tissue 
shielding) this time and associated data were excluded from the calcu-
lations. The fluence rate’s mean, standard deviation (SD) and range i.e. 
maximal and minimal values were calculated. Every measured fluence 
rate over time per single probe was divided into intervals of 40 
mW⋅cm  2. The percentage of the total light exposure time measured 
within the interval was calculated. In order to determine the spatial 
variation, a description of the light exposure per isotropic detector probe 
was performed in the patients with two probes positioned within the 
same cavity during illumination. A descriptive analysis was chosen in 
the absence of enough data for statistical substantiation. 
3. Results 
Multiple types of target locations were treated including the naso-
pharynx, maxillary sinus, sphenoid sinus, frontal sinus, as well as the 
anterior skull base. In four patients the fluence rate and fluence was 
measured by using two isotropic detector probes at two different loca-
tions within the cavity. In seven patients we used a single isotropic de-
tector probe. There was a large variability in type of light diffuser used, 
the laser output and light exposition time. An overview of the target area 
location, number of isotropic detector probes and type of light diffuser is 
shown in Table 1. The goal was to illuminate until a fluence of ~20 
J⋅cm  2 was achieved, therefore the illumination duration varied for 
each individual PDT session. In five probes in four different patients the 
total measured fluence was around 10 J⋅cm  2 because of different rea-
sons, including a too long light exposure time to reach the 20 J⋅cm-2 or a 
second probe which reached a total dose of 20 J⋅cm-2 earlier. Besides, in 
for example patient C, a total light dose of 10 J⋅cm  2 was deliberately 
chosen to limit the risk of cerebrospinal fluid leakage when illuminating 
the anterior skull base. In two patients (two isotropic detector probes) a 
total light dose far above the 20 J⋅cm-2 was measured. This total light 
dose was high because multiple target areas were all illuminated sepa-
rately using a micro-lens diffuser until a light dose of 20 J⋅cm-2 was 
accomplished. In patient J, three different regions within the target area 
were illuminated, whereas in de last illumination the isotropic detector 
probe was removed after 40 s because it interfered with the exposure of 
light at the target area. 
3.1. Temporal variation 
All measurements showed major fluence rate fluctuations for a single 
isotropic detector probe over time. These fluctuations occur despite the 
surgeons attempt to keep the probe stable within the target area. An 
example of the fluence and fluence rate over time measured within one 
isotropic detector probe is shown in Fig. 3. The largest difference be-
tween the minimal and maximal measured fluence rate during light 
exposure was 328 mW⋅cm  2. An overview of the measured fluence rate 
range and mean per isotropic detector probe is shown in Table 2. The 
aim was to stably illuminate with approximately 80  120 mW⋅cm  2 at 
the target area. In only one probe a mean fluence rate within this range 
was measured (probe 7, mean fluence rate ~103 mW⋅cm  2). However, 
this fluence rate was reached with an extreme duration of light 
Fig. 2. PDT and dosimetry measurement set up in the operation room. Photodynamic therapy illumination of a paranasal sinus by endoscopic approach. A: the (red) 
laser light source and the isotropic detector probe are hand-held by a surgeon during illumination and in vivo light dosimetry. B  C: Endoscopic view of the sinonasal 
target area prior to illumination (B) and during illumination (C). The asterisk (*) shows the isotropic detector probe and the spherical light diffuser is indicated by 
the arrow. 
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exposition (2283 s) and a large range with a minimal measured fluence 
rate of ~8 mW⋅cm  2 and maximal fluence rate of ~289 mW⋅cm  2. 
Probe 10 showed the most stable measured fluence rate, in circa 87 
percent of the illumination time the fluence rate was between 20  40 
mW⋅cm  2. In addition, probe 5 showed fairly stable fluence rates, all 
within 40  80 mW⋅cm  2. See Table 3 for the percentage measured flu-
ence rate per isotropic detector probe over time. In all isotropic detector 
probes taken together, there was in 22 % of the time a fluence rate 
measured of less than 20 mW⋅cm  2. In 31 % of the illumination time of 
all probes, a fluence rate above the 80 mW⋅cm  2 was measured. An 
overview of the fluence rates divided into categories of 40 mW⋅cm  2 
over the light exposure time can be seen in Fig. 4. Usually when treating 
head and neck malignancies with PDT, the light exposure time is set to 
200 s at 100 mW⋅cm  2. In this cohort in 33 % (5 probes) a light dose of at 
least 20 J⋅cm  2 was measured after 200 s of illumination. Which means 
that if no dosimetry was used in these patients and the light exposition 
durance was set to 200 s, the target area in the majority would have been 
underexposed (less than 20 J⋅cm  2). 
3.2. Spatial variation 
In four patients two individual probes were used to measure the 
fluence rate at two different locations. In all patients there was a large 
spatial variation between the measured fluence rates at the two different 
positions within the cavity. The fluence rate course of the two probes of 
patient A, C, G and H is shown in Fig. 5. A reasonable stable fluence rate 
was measured for a longer period at the end of the illumination in pa-
tient C and G. The greatest variability in fluence rate in both isotropic 
detector probes was seen in patient A. In patient G there may be a slight 
negative correlation visible, showing that if the fluence rate in probe 9 
decreases, the fluence rate in probe 10 increased. 
Fig. 3. Graph above: The measured fluence rate (Y-axis) plotted over time (X-axis) within one isotropic detector in patient F. This demonstrates that the fluence rate 
does not show a stable straight line but many fluctuations over time, so there is a large temporal variability. Graph below: The fluence (i.e. light dose) on the Y-axis, 
plotted over time (X-axis). The illumination was stopped if the aimed fluence rate of 20 J⋅cm  2 was reached. 
Table 2 
An overview of the measured in vivo light dosimetry characteristics per isotropic detector probe.  
Isotropic detector 






















Mean fluence rate 




200 s light 
exposure 
J⋅cm  2 
1, A 301 20.3 26.7 130.1 103.4 67.4 32.8 48.1 9.6 
2, A 301 18.9 18.4 102.5 84.1 62.7 21.9 69.7 14.0 
3, B 760 10.8 0.1 56.5 56.4 13.5 8.9 10.2 2.1 
4, C 164 10.7 53.6 123.8 70.2 65.4 14.7 65.4 10.7 
5, C 164 10.0 53.4 75.2 21.7 61.2 6.1 61.2 10.0 
6, D 200 24.6 46.1 197.6 151.5 122.9 33.0 122.9 24.6 
7, E 2283 236.2 8.3 289.7 281.4 103.3 50.9 158.6 31.7 
8, F 747 20.0 2.4 277.8 275.4 26.5 22.1 30.3 6.3 
9, G 565 7.4 8.2 33.5 25.3 13.1 3.7 15.9 3.2 
10, G 565 20.2 18.1 59.9 41.9 35.7 6.6 30.4 6.1 
11, H 163 28.9 110.9 218.8 107.9 176.6 20.4 176.6 28.7 
12, H 163 20.1 51.3 160.9 109.7 123.6 15.7 123.6 20.1 
13, I 804 23.9 0.1 154.8 154.7 29.2 22.9 22.4 4.6 
14, J 471 35.2 17.6 345.4 327.8 74.0 44.9 105.8 21.2 
15, K 400 6.3 4.4 21.4 17.0 15.8 4.9 12.4 2.5  
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4. Discussion 
In this clinical dosimetric study during sinonasal mTHPC-mediated 
PDT, large temporal and spatial variations in fluence rate were 
observed. In which it proved to be very challenging to deliver a stable, 
homogeneous and desired fluence rate and fluence to the target area as 
expected according to previous research [10,12–15,19,24]. According to 
the European Medicine Agency patients were treated with a mTHPC 
dose of 0.15 kg/mg and a drug-time interval of 4 days. Previous studies 
have shown that the time-interval as well as different drug dose may 
improve the PDT treatment effect and show less toxicity to the patient 
[25–28]. However, drug dose as well as drug-light interval were outside 
the scope of this study. There are a number of limitations, when using 
the current dosimetry and PDT approach, which affect these variations. 
First, the dosimetric approach used merely utilizes a simple, first 
order calculation of the expected direct incident fluence rate for an 
estimated ‘optimal’ source location in relation to the target area. This 
method was in particular based on the source output and the distance 
between the light source and the target area, determined using CT or MR 
imaging. A number of essential influential aspects were not taken into 
account within this approach including: the optical properties with 
scattering and absorption values, the complex geometry of the paranasal 
cavity with grooves, niches and corners, the influence of back-scattering 
with the associated fluence rate build-up and 3D light distribution 
[12–14,29]. 
Additionally, an attempt was made to reach the pre-determined 
preferred light source location during the PDT manually by the sur-
geon. However, the only feedback in reaching this optimal location is 
the inaccurate use of the two dimensional endoscopic view. Further-
more, the manual positioning causes, despite the surgeon’s steady hand, 
small movements resulting in variation in distance between the source 
and probes and therefore fluence rate variations. The use of reflecting 
elastic balloons with an incorporated light source are found to be of 
added value in PDT [17,30,31]. The possibility for use within the par-
anasal sinuses has yet to be explored, but might be challenging due to 
the wide variation of the sinus anatomy, especially after salvage surgery. 
In case of an elongated smooth cylindrical cavity, a linear diffuser with 
balloon applicator could be considered. However, the balloon might put 
pressure on the mucosa, thereby compressing the capillaries, hindering 
the oxygen supply necessary for PDT. 
In addition, an attempt was made to place the isotropic detectors in 
the target area, ideally in direct view of the light source with minimal 
interference with the light exposure in the target area. Due to the 
anatomy and the passage of the isotropic detector probes via the nasal 
cavity, parallel to the light source and endoscope, this results in a 
sideway position of the probe related to the light source, which might 
lead to an under estimation of the actual fluence rate. Fig. 4 shows that 
in this study the majority of measured fluence rate was below the 80 
mW⋅cm  2. Overall, the current approach lacks in reliable quantitative 
dosimetric feedback and verification of the actual position of, and dis-
tances between the light source, isotropic detector probe(s) and target 
area. 
Moreover, there are intra- and interpatient variations in optical 
properties whereas the paranasal cavity surface is irregular and con-
sisting of different coverings such as intact mucosa, affected mucosa, 
scar tissue, crusts and exposed bone [5,32–34]. In addition, during the 
light exposure, the optical properties can change due to instant vascular 
effects of the PDT [3,19,35] and thus results in an increase or decrease in 
measured fluence rate. 
The spatial variations are difficult to quantify due to the complexity 
of the sinonasal geometry and the aforementioned heterogeneous dis-
tribution of the optical properties. Besides, conclusions in spatial vari-
ation could not be drawn because the exact distances between the light 
source, the isotropic detector probes and target area were unknown. In 
addition, a maximum of two measuring isotropic probes within the 
cavity is not sufficient to get a reliable impression of the global light 
distribution in the 3D space of the sinonasal cavity, as the probes were 
mainly positioned in, or in the vicinity of the target area. 
Finally, due to the limited patient numbers, variability of geometry 
and optical properties within the target location, light diffuser type 
Table 3 
This table shows the percentage of the total light exposure time per individual isotropic detector probe during in vivo light dosimetry were a fluence rate was measured 
within categories of 40 mW⋅cm  2.  
Isotropic detector probe 
number and patient letter 
Fluence rate 0–40 
mW⋅ cm  2 
(%time) 
Fluence rate 41–80 
mW⋅cm  2 
(%time) 
Fluence rate 81–120 
mW⋅cm  2 
(%time) 
Fluence rate 121–160 
mW⋅cm  2 
(%time) 
Fluence rate 161–200 
mW⋅cm  2 
(%time) 
Fluence rate >200 
mW⋅cm  2 
(%time) 
1, A 24 36 39 1 – – 
2, A 21 54 25 – – – 
3, B 97 3 – – – – 
4, C – 86 13 1 – – 
5, C – 100 – – – – 
6, D – 1 63 20 16  
7, E 15 25 15 30 14 1 
8, F 84 14 1 1 – – 
9, G 100 – – – – – 
10, G 88 12 – – – – 
11, H – – 1 16 70 13 
12, H – 1 36 62 1 – 
13, I 77 19 3 1 – – 
14, J 16 47 31 4 – 2 
15, K 100 – – – – –  
Fig. 4. An overview of the percentage of measured fluence rate of the total 
illumination time in all isotropic detector probes taken together. The fluence 
rate is divided in categories of 40 mW⋅cm  2 size. 
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employed and source output used, no definitive conclusions regarding 
the exact origin of the observed variation in fluence rate can be drawn. 
Also in view of the limited number of patients and aforementioned 
variations, no statement could be made in this cohort about the clinical 
response to the PDT in relation to the fluence rate. 
5. Conclusion & future perspectives 
In conclusion, the current paranasal sinus PDT dosimetry approach 
demonstrated major temporal and spatial variations in fluence rate and 
fluence. Despite the promising clinical results [20,22], the current 
approach is not reproducible, neither standardized and inaccurate. On 
account of manually positioning of the light source and isotropic de-
tector probes, and an inaccurate pre-treatment planning of the desired 
source location. 
In light of these limitations, our group is directing future research to 
develop a reliable dosimetric approach that allows for sinonasal 
dosimetry pre-planning in 3D. This model will take the tissue back 
scattering i.e. tissue optical properties into account to determine the 
most optimal source location(s), output power and light diffuser type 
[36]. Previous research demonstrated that the fluence rate distribution 
can be determined in tissue optical phantoms that closely match the 
target area geometry and optical properties [6,19]. Our developed 3D 
models are therefore tested and based on 3D phantoms with a 
patient-specific paranasal sinus geometry and known optical properties. 
Employing electromagnetic navigation can assist in positioning the 
isotropic detector probes and light source to the pre-determined optimal 
locations and allows direct visual feedback of the actual positions during 
the light exposure [37]. Besides, a fixation tool will be developed to 
enable a stable fluence rate delivery, whereas several studies showed a 
reduction of instrument movements by using a surgical robot device 
compared to manual surgery [38,39]. In addition, the in vivo optical 
properties of the paranasal sinus will be determined by means of mul-
tidiameter single-fiber reflectance (MDSFR) spectroscopy; these prop-
erties will be incorporated in this developed 3D light distribution model. 
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